Cargando…

Immunohistochemical study of CD117 in various cutaneous melanocytic lesions

The aim of the present study was to carried out a comparative immunohistochemical evaluation of CD117 (c-Kit), a biomarker that evaluates both tumor progression and prognosis, in different melanocytic lesions, to emphasize the significance of this biomarker in malignant melanoma (MM). The study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Radu, Antonia, Bejenaru, Cornelia, Ţolea, Ion, Maranduca, Minela Aida, Brănişteanu, Daniel Constantin, Bejenaru, Ludovic Everard, Petrariu, Florin Dumitru, Stoleriu, Gabriela, Brănişteanu, Daciana Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725021/
https://www.ncbi.nlm.nih.gov/pubmed/33363589
http://dx.doi.org/10.3892/etm.2020.9510
_version_ 1783620628287324160
author Radu, Antonia
Bejenaru, Cornelia
Ţolea, Ion
Maranduca, Minela Aida
Brănişteanu, Daniel Constantin
Bejenaru, Ludovic Everard
Petrariu, Florin Dumitru
Stoleriu, Gabriela
Brănişteanu, Daciana Elena
author_facet Radu, Antonia
Bejenaru, Cornelia
Ţolea, Ion
Maranduca, Minela Aida
Brănişteanu, Daniel Constantin
Bejenaru, Ludovic Everard
Petrariu, Florin Dumitru
Stoleriu, Gabriela
Brănişteanu, Daciana Elena
author_sort Radu, Antonia
collection PubMed
description The aim of the present study was to carried out a comparative immunohistochemical evaluation of CD117 (c-Kit), a biomarker that evaluates both tumor progression and prognosis, in different melanocytic lesions, to emphasize the significance of this biomarker in malignant melanoma (MM). The study was performed on 55 cases, represented by a control group, which included 5 cases of simple nevi and 5 cases of dysplastic nevi, as well as a study group consisting of 35 cases of primary MM and 10 metastases (one intestinal, 3 cutaneous - one satellite and two distant as well as 6 in the lymph nodes). The study group included 15 cases of superficial spreading melanoma (SSM), 10 cases of nodular melanoma (NM), 3 lentigo maligna melanoma (LMM), 3 cases of acral lentiginous melanoma (ALM) and 4 cases of amelanotic MM. CD117 was found to be massively involved in the process of tumorigenesis of cutaneous malignancies, being immunohistochemically undetectable in benign neural lesions, but densely expressed in dysplastic lesions and in situ melanoma areas. In invasive cutaneous MMs, CD117 expression tended to decrease with neoplasia progression proceding into the tumorigenic, vertical growth phase, being lower in the profound dermal component of tumors and in nodular MMs. To eliminate the epidermal barriers and gain a proliferative advantage to allow the transition to the vertical growth phase, it seems that MM should lose expression of c-Kit. Cutaneous metastases were found to express CD117 at a level comparable to their primary tumors, suggesting that other mechanisms interfere directly with the metastatic process and not loss of c-Kit expression by itself. CD117 overexpression in cutaneous melanocytic lesions correlates significantly with increased immunostaining intensity, suggesting that the immunohistochemical evaluation of CD117 may be a good method for screening patients, who could benefit from personalized therapy with tyrosine kinase inhibitors.
format Online
Article
Text
id pubmed-7725021
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-77250212020-12-23 Immunohistochemical study of CD117 in various cutaneous melanocytic lesions Radu, Antonia Bejenaru, Cornelia Ţolea, Ion Maranduca, Minela Aida Brănişteanu, Daniel Constantin Bejenaru, Ludovic Everard Petrariu, Florin Dumitru Stoleriu, Gabriela Brănişteanu, Daciana Elena Exp Ther Med Articles The aim of the present study was to carried out a comparative immunohistochemical evaluation of CD117 (c-Kit), a biomarker that evaluates both tumor progression and prognosis, in different melanocytic lesions, to emphasize the significance of this biomarker in malignant melanoma (MM). The study was performed on 55 cases, represented by a control group, which included 5 cases of simple nevi and 5 cases of dysplastic nevi, as well as a study group consisting of 35 cases of primary MM and 10 metastases (one intestinal, 3 cutaneous - one satellite and two distant as well as 6 in the lymph nodes). The study group included 15 cases of superficial spreading melanoma (SSM), 10 cases of nodular melanoma (NM), 3 lentigo maligna melanoma (LMM), 3 cases of acral lentiginous melanoma (ALM) and 4 cases of amelanotic MM. CD117 was found to be massively involved in the process of tumorigenesis of cutaneous malignancies, being immunohistochemically undetectable in benign neural lesions, but densely expressed in dysplastic lesions and in situ melanoma areas. In invasive cutaneous MMs, CD117 expression tended to decrease with neoplasia progression proceding into the tumorigenic, vertical growth phase, being lower in the profound dermal component of tumors and in nodular MMs. To eliminate the epidermal barriers and gain a proliferative advantage to allow the transition to the vertical growth phase, it seems that MM should lose expression of c-Kit. Cutaneous metastases were found to express CD117 at a level comparable to their primary tumors, suggesting that other mechanisms interfere directly with the metastatic process and not loss of c-Kit expression by itself. CD117 overexpression in cutaneous melanocytic lesions correlates significantly with increased immunostaining intensity, suggesting that the immunohistochemical evaluation of CD117 may be a good method for screening patients, who could benefit from personalized therapy with tyrosine kinase inhibitors. D.A. Spandidos 2021-01 2020-11-26 /pmc/articles/PMC7725021/ /pubmed/33363589 http://dx.doi.org/10.3892/etm.2020.9510 Text en Copyright: © Radu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Radu, Antonia
Bejenaru, Cornelia
Ţolea, Ion
Maranduca, Minela Aida
Brănişteanu, Daniel Constantin
Bejenaru, Ludovic Everard
Petrariu, Florin Dumitru
Stoleriu, Gabriela
Brănişteanu, Daciana Elena
Immunohistochemical study of CD117 in various cutaneous melanocytic lesions
title Immunohistochemical study of CD117 in various cutaneous melanocytic lesions
title_full Immunohistochemical study of CD117 in various cutaneous melanocytic lesions
title_fullStr Immunohistochemical study of CD117 in various cutaneous melanocytic lesions
title_full_unstemmed Immunohistochemical study of CD117 in various cutaneous melanocytic lesions
title_short Immunohistochemical study of CD117 in various cutaneous melanocytic lesions
title_sort immunohistochemical study of cd117 in various cutaneous melanocytic lesions
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725021/
https://www.ncbi.nlm.nih.gov/pubmed/33363589
http://dx.doi.org/10.3892/etm.2020.9510
work_keys_str_mv AT raduantonia immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT bejenarucornelia immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT toleaion immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT maranducaminelaaida immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT branisteanudanielconstantin immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT bejenaruludoviceverard immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT petrariuflorindumitru immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT stoleriugabriela immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions
AT branisteanudacianaelena immunohistochemicalstudyofcd117invariouscutaneousmelanocyticlesions